ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1159

IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study

Hadeel Abdul-Rehman1, Karen Gambina2 and Bella Mehta3, 1Hospital for Special Surgery, New York, NY, 2Columbia University Medical Center, Islip, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Biomarkers, Disease Activity, Still's disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising indicator of disease activity and potential target for therapeutics. The Pouchot systemic score, used to evaluate disease activity, assigns 1 point to each: fever, rash, pleuritis, pneumonia, pericarditis, hepatomegaly, splenomegaly, lymphadenopathy, leukocytosis ( >15,000/μL), sore throat, myalgia, and abdominal pain. The modified Pouchot (mPochout) score replaces splenomegaly and myalgia with arthralgia and hyperferritinemia ( >3000 μg/L). We evaluated the association between serum IL-18 levels and disease activity as measured by Pouchot scores in patients with AOSD to assess the potential of IL-18 as a biomarker.

Methods: Patients were identified by ICD-10 codes, and diagnoses were confirmed by their treating rheumatologist and via chart review by rheumatologists. Pouchot/mPouchot scores were calculated from the same day IL-18 labs were checked. We used linear mixed-effects models to assess the association between log-transformed IL-18 levels and clinical/serologic markers of disease activity, including Pouchot/mPouchot score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and ferritin. Patient ID was included as a random effect to account for repeated measures. Fixed effects included the independent variable of interest (e.g., Pouchot score), with IL-18 as the dependent variable. We also measured intraclass correlation coefficients (ICC).

Results: Of the Pouchot score symptoms, arthritis was the most common, followed by hepatomegaly, myalgia, rash, and fever. The mean Pouchot score, mPouchot score, and IL-18 level across all visits were 1.2, 1.7, and 14041.8 pg/mL respectively. Pouchot scores, ESR levels, and ferritin levels showed significant positive associations with IL-18 levels: (p< 0.01, p < 0.05, p < 0.001). The association between mPouchot scores or CRP with IL-18 levels were not statistically significant. ICC for the Pouchot, mPouchot, ESR, CRP, and Ferritin models ranged from 0.75-0.84 across models thus indicating 75-84% of variability in IL-18 levels was due to between-subject differences, while 16-25% was due to within-subject variability.

Conclusion: These findings suggest the potential utility of IL-18 as a biomarker for disease monitoring in AOSD, particularly in combination with clinical activity scores such as the Pouchot score, given its strong association with disease activity markers and its stable inter-individual variability over time. Given newer potential therapeutics in AOSD, regular IL-18 and disease activity monitoring may be useful in management of these patients.1. Colafrancesco et al. IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity. PMID: 22762008.

Supporting image 1Table 1. Demographic and Clinical Characteristics

Supporting image 2Table 2. Results of Linear Mixed-Effects Models Assessing the Association Between Disease Activity and Inflammatory Markers with Log-Transformed IL-18 Levels

Supporting image 3Figure 1: Log-Transformed IL-18 Levels vs Pouchot Score. Data points represent individual visits during which IL-18 levels were checked and Pouchot scores were calculated; different colors correspond to different patients. A line of best fit was constructed for patients that were tested more than once. Higher Pouchot scores indicate more severe disease activity.


Disclosures: H. Abdul-Rehman: None; K. Gambina: None; B. Mehta: Amgen, 1, Horizon, 1.

To cite this abstract in AMA style:

Abdul-Rehman H, Gambina K, Mehta B. IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/il-18-correlates-with-pouchot-score-and-inflammatory-biomarkers-in-adult-onset-stills-disease-insights-from-a-repeated-measures-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-18-correlates-with-pouchot-score-and-inflammatory-biomarkers-in-adult-onset-stills-disease-insights-from-a-repeated-measures-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology